for PTH concentrations of <100 pg/mL, 100 to <200 pg/mL, 300 to <400 pg/mL, 400 to <500 pg/mL, 500 to <600 pg/mL, 600 to <700 pg/mL, and ≥700 pg/mL respectively. Compared with PD patients having serum concentrations of ALP and PTH within reference ranges, patients on HD experienced increased mortality across all ALP and PTH concentrations, particularly those in the lowest and highest categories. ♦ Conclusions: In summary, higher ALP concentrations are associated with increased mortality, and lower and higher PTH concentrations are both associated with death risk in PD patients. The utility of ALP in the management of chronic kidney disease mineral bone disorders in PD patients warrants further study.
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PDI NOVEMBER 2014 -VOL. 34, NO. 7 OSTEODYSTROPHY MARKERS AND DIALYSIS MODALITY traditional risk factors (1) . In dialysis patients, chronic kidney disease mineral bone disorders (CKD-MBD) are exceedingly common and have been implicated as nontraditional risk factors for cardiovascular morbidity and mortality (2) . Guidelines from Kidney Disease Improving Global Outcomes recommend serum alkaline phosphatase (ALP) and parathyroid hormone (PTH) as adjunctive tests in the assessment of bone turnover, and mounting evidence suggests that derangements in these biomarkers are associated with coronary artery calcification, cardiovascular events, sudden cardiac death, and increased mortality in non-dialysis-dependent CKD and hemodialysis (HD) patients (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . However, controversy remains about whether there is additive value for ALP in addition to PTH in CKD-MBD management (15) (16) (17) .
Serum ALP is a metalloenzyme with wide tissue distribution, but with particularly high concentrations in bone, liver, intestine, and placenta (18) . The bone isoform of ALP is produced by osteoblasts and may be a more specific indicator of bone turnover than is PTH, which originates from the parathyroid glands and is influenced by age, race, suboptimal assays, inflammation, and nutrition and anthropometric status (19) (20) (21) (22) (23) . Experimental data suggest that ALP may be causally associated with vascular calcification via hydrolysis of pyrophosphate, a potent calcification inhibitor (18, 24, 25) . Vascular calcification is a measure of atherosclerotic burden and-through effects on arterial compliance, pulse pressure, and afterload-might also contribute to ventricular hypertrophy and impaired coronary perfusion (26) . Moreover, it is highly correlated with cardiovascular morbidity and mortality in dialysis patients (27) . Based on those data, ALP derangements might be inferred to be an important risk factor for mortality in dialysis patients.
Data from the US Renal Data System show that the incident PD population is rapidly growing and now accounts for 7% of dialysis patients (28) . It is plausible that bone metabolism and morphology may be inherently different in PD and HD patients because of the heightened risk of vitamin D deficiency associated with peritoneal effluent losses and because of differences in CKD-MBD management in PD-specifically, greater use of oral vitamin D in lieu of intravenous forms (29) . To date, few studies have examined the associations of ALP and PTH with mortality in PD patients.
We hypothesized that ALP and PTH derangements are associated with mortality in both PD and HD patients. We conducted the present study to examine the associations of serum ALP and PTH concentrations with mortality in PD patients, and to compare mortality-predictability using those markers in HD and PD patients in a large contemporary cohort of dialysis patients having detailed laboratory data and extended follow-up over which to observe outcomes.
METHODS

STUDY POPULATION
We examined data for all end-stage renal disease patients undergoing HD or PD in one of the DaVita outpatient dialysis facilities from 1 July 2001 to 30 June 2006. Patients were followed for outcomes through 30 June 2009. Each patient's baseline quarter was the calendar quarter of entry into the cohort, and the ascribed dialysis modality was the modality in use in the baseline quarter. Patients were included provided that they were 18 years of age or older, had 1 or more ALP and PTH measurements in the baseline quarter, and had no missing data for key covariates or for follow-up time.
The study was approved by the Institutional Review Committees of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and DaVita Clinical Research. Given the large sample size, the anonymity of the study patients, and the nonintrusive nature of the research, requirement for consent was exempted.
SOCIODEMOGRAPHIC, COMORBIDITY, AND LABORATORY MEASUREMENTS
The creation of the cohort has previously been described (30) . To minimize measurement variability, all repeated clinical and laboratory measurements for each patient during any 13-week calendar quarter were averaged for up to 20 entry calendar quarters (1 July 2001 through 30 June  2006) , and summary estimates were used in all models. Sociodemographic information and presence of diabetes were obtained from the DaVita database.
Data on baseline comorbidities were obtained by linking the DaVita database to US Renal Data System Medical Evidence Form 2728 data, and the results were categorized into these cardiovascular comorbidities: congestive heart failure, peripheral vascular disease, atherosclerotic heart disease, and other cardiovascular diseases.
In all DaVita dialysis clinics, blood samples were drawn using standardized techniques and were transported to the DaVita laboratory in Deland, Florida, typically within 24 hours, where they were measured using automated and standardized methods. Most laboratory parameters, including serum ALP, were measured monthly, and serum intact PTH was measured at least quarterly using a firstgeneration immunoradiometric PTH assay (Nichols, San Juan Capistrano, CA, USA) (31) . In co-primary analyses, we examined how ALP and PTH concentrations, separately, were associated with all-cause mortality. Serum ALP was divided into 10 a priori categories: <50 U/L, 50 to <70 U/L, 70 to <90 U/L, 90 to <110 U/L, 110 to <130 U/L, 130 to <150 U/L, 150 to <170 U/L, 170 to <190 U/L, 190 to <210 U/L, and ≥210 U/L. Serum PTH was divided into 8 a priori categories: <100 pg/mL, 100 to <200 pg/mL, 200 to <300 pg/mL, 300 to <400 pg/mL, 400 to <500 pg/mL, 500 to <600 pg/mL, 600 to <700 pg/ mL, and ≥700 pg/mL. In secondary analyses, we examined mortality-predictability using low ALP (<120 U/L) compared with high ALP (≥120 U/L) within strata of low PTH (<300 pg/mL) and high PTH (≥300 pg/mL). The ALP cut-off was selected based on the threshold above which increased morbidity and mortality have been observed in earlier studies (11, 12, 32) , and the PTH cut-off was selected based on the threshold above which treatment of secondary hyperparathyroidism is recommended in the Kidney Disease Outcomes Quality Initiative guidelines (33) .
OUTCOME ASCERTAINMENT
The outcome of interest was all-cause death ascertained from the DaVita database and the US Renal Data System database linkage. Patients were followed for the outcome of interest until death or censoring for transplantation, transfer to a non-DaVita dialysis clinic, or end of the study (30 June 2007) .
STATISTICAL ANALYSES
Baseline characteristics of the patients with high and low ALP within the strata of high and low PTH were compared using analysis of variance, Kruskal-Wallis, and chi-square tests as dictated by data type. The associations of baseline and time-averaged ALP with mortality in PD patients were examined using Cox proportional hazards regression. Pooled analyses were used to evaluate the mortality-predictability for baseline and time-averaged ALP in HD and PD patients. Analogous analyses were used to examine the associations of baseline and timeaveraged serum PTH with mortality in PD patients, and to compare mortality-predictability using baseline and time-averaged PTH in HD and PD patients.
For each analysis, three sequential models, with incremental multivariable adjustment for baseline covariates, were examined:
• Unadjusted models included the exposure of interest and the entry calendar quarter (to account for ALP and PTH assay drift)
• Case-mix adjusted models included all covariates in the unadjusted models, plus age, sex, race or ethnicity (non-Hispanic African American, nonHispanic white, Hispanic, and Asian, with the first two groups hereafter referred to as "black" and "white" respectively), diabetes, baseline cardiovascular comorbidities, active tobacco use, dialysis vintage, primary insurance, marital status, body mass index, and ferritin • Case-mix plus laboratory-adjusted models ("fullyadjusted") included all covariates in the case-mix adjusted models, plus laboratory surrogates of nutrition and inflammation (serum albumin, total iron binding capacity, bicarbonate, creatinine, white blood cell count, lymphocyte percentage, normalized protein catabolic rate), calcium, phosphorus, hemoglobin, and weekly dose of an erythropoiesisstimulating agent
Given that elevated ALP concentrations can also be observed with liver disease, the fully-adjusted analyses of ALP and mortality were repeated with additional adjustment for serum aspartate aminotransferase (AST) as sensitivity analyses. Missing covariate data were imputed as appropriate. Plots of log[-log(survival rate)] against log(survival time) were used to check the proportionality assumption. All calculations were conducted using the SAS software application (version 9.1: SAS Institute, Cary, NC, USA) and Stata MP (version 10.1: StataCorp LP, College Station, TX, USA).
RESULTS
COHORT DESCRIPTION
After excluding patients not on PD or HD during the baseline quarter, less than 18 years of age, or with missing data for ALP, PTH, key covariates, or follow-up time, the final study cohort consisted of 108 567 patients among whom 9244 were on PD and 99 323 were on HD ( Figure 1) . Examination of meaningful differences in baseline characteristics for the included and excluded patients receiving dialysis during the baseline quarter demonstrated that those who were excluded were less likely to be black or Hispanic or to receive Medicare or Medicaid; likely to be white and to have a shorter dialysis vintage and atherosclerotic heart disease; and likely to have lower mean creatinine and ferritin concentrations ( Table 1) .
Concentrations of ALP were similar in PD and HD patients, and more than 60% of the patients using either treatment modality had an ALP concentration less than 110 U/L [typical reference range: 25 -100 U/L (34); Figure 2 ]. However, PD patients manifested a higher prevalence of PTH exceeding 300 pg/dL (48.1% vs 39.4% of HD patients) and PTH exceeding 600 pg/dL (20.1% vs 13.8% of HD patients). Compared with HD treatment, PD treatment was associated with a higher risk of having a PTH concentration exceeding 300 pg/dL or exceeding 600 pg/dL after adjustment for case-mix and laboratory covariates [odd ratios (95% confidence intervals): 1.68 (1.60 to 1.76) and 1.73 (1.62 -1.84) respectively; Table 2 ].
In terms of baseline characteristics, patients with high turnover markers (concordantly high ALP and PTH) were more likely to be younger, female, black, and of longer dialysis vintage. They were less likely to be white or diabetic, or to have atherosclerotic heart disease, and they had higher mean creatinine and ferritin concentrations than did patients with low turnover markers (concordantly low ALP and PTH, Table 3 ).
ALP AND MORTALITY IN PD PATIENTS
The median follow-up time for the cohort was 2.7 years (interquartile range: 1.3 -4.3 years), during which time 
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PDI 56 005 all-cause deaths occurred. In analyses considering baseline measurements, higher ALP concentrations were associated with increased mortality among PD patients in the unadjusted, case-mix, and fully-adjusted analyses [ Figure 3 (A), Table 4 ]. In the fully-adjusted analyses, ALP concentrations less than 50 U/L were associated with lower mortality, and ALP concentrations exceeding 90 U/L were associated with higher mortality (reference ALP: 70 to <90 U/L). Sensitivity analyses adjusted for AST were qualitatively similar (Table 5 ). When the data were examined in quintiles, a graded association between higher ALP quintile and mortality was evident ( Figure 4 ). In fully-adjusted analyses considering time-averaged measurements, we observed a J-shaped association between ALP concentration and mortality in PD patients [ Figure 3 (B), Table 4 ]. Concentrations of ALP less than 70 U/L were not associated with lower mortality, but ALP concentrations exceeding 150 U/L were associated with higher mortality (reference ALP: 70 to <90 U/L). Sensitivity analyses adjusted for AST were qualitatively similar (Table 5) .
When baseline ALP and PTH concentrations were jointly considered (with patients having concordantly low ALP and PTH as the reference), mortality was increased in patients with high ALP regardless of PTH stratum, but patients with low ALP and high PTH were not at increased risk (Table 6 ).
PTH AND MORTALITY IN PD PATIENTS
In analyses considering baseline measurements, the associations of PTH concentrations with all-cause mortality in PD patients varied in the unadjusted, case-mix, and fully-adjusted analyses [ Figure 5 (A), Table 4 ]. In fully-adjusted analyses, higher PTH and mortality were not significantly associated. However, when examined in quintiles, a J-shaped association between higher PTH quintile and mortality was observed ( Figure 4) .
In analyses considering time-averaged measurements, the associations of PTH concentrations with all-cause mortality in PD patients varied in the unadjusted, casemix, and fully-adjusted analyses [ Figure 5 (B), Table 4 ]. In fully-adjusted analyses, we observed a U-shaped PTH-mortality association in which PTH concentrations less than 200 pg/mL and 600 pg/mL or greater were associated with increased mortality (reference PTH: 200 to <300 pg/mL).
MORTALITY-PREDICTABILITY USING ALP AND PTH IN HD AND PD PATIENTS
Among HD and PD patients, the mortality-predictability using ALP concentrations was compared in fully-adjusted analyses. In analyses of baseline ALP values (PD patients with ALP 70 to <90 U/L being the reference), incrementally higher ALP values showed a relatively linear association with mortality in HD and PD patients alike [ Figure 6 (A), Table 7 ]. In analyses of time-averaged ALP measurements, HD patients experienced increased mortality at all concentrations, with the greatest risk occurring in the highest and lowest ALP categories. In contrast, PD patients experienced increased mortality with ALP values exceeding 150 U/L [ Figure 6 (B), Table 7 ]. Sensitivity analyses adjusted for AST were qualitatively similar (Table 8) .
In HD and PD patients, the mortality-predictability using PTH concentrations was compared in fully-adjusted analyses (PD patients having a PTH value of 200 to <300 pg/mL being the reference group). In analyses of baseline PTH values, we observed a relatively linear association between higher PTH and mortality in HD patients; in PD patients, the lowest PTH category was associated with a survival benefit [ Figure 7 (A), Table 7 ]. In analyses of time-averaged PTH measurements, HD BMI = body mass index; CHF = congestive heart failure; AHD = atherosclerotic heart disease; PVD = peripheral vascular disease; IQR = interquartile range; TIBC = total iron-binding capacity; WBC = white blood cell. Figure 7 (B), Table 7 ].
DISCUSSION
In this large, contemporary cohort of PD patients, we examined associations between biochemical markers of bone turnover and all-cause mortality. In analyses of baseline and time-averaged measurements, we found a significant association between higher serum ALP and mortality in PD patients that remained robust in multiple secondary and sensitivity analyses. We also observed a U-shaped association between time-averaged PTH and mortality in PD patients.
Elevated serum ALP might contribute to increased mortality by several mechanisms. Although found in a diverse set of tissues, ALP, when elevated, is commonly considered a marker of high bone turnover in dialysis patients (3, 18) . However, increasing evidence suggests that ALP is not simply a marker of poor bone health, but that it might also be a mediator of vascular calcification, which is a predictor of mortality in dialysis patients (18, 24, 25) . In animal studies, nonspecific ALP has been shown to hydrolyze pyrophosphate, which is a potent inhibitor of vascular calcification that prevents incorporation of inorganic phosphate into hydroxyapatite crystals (24, 25) . Alkaline phosphatase has been shown to be upregulated in calcified diabetic arteries and in the blood vessels of kidney disease patients with calciphylaxis (35, 36) . In animal models, genetic ablation of tissue-nonspecific ALP has been shown to ameliorate vascular calcification (37) . Additionally, levamisole, a nonspecific ALP inhibitor, has been shown to reduce the hydrolysis rate of pyrophosphate in uremic rat aortas (25) . Emerging data demonstrating an association between ALP and coronary artery calcification, cardiovascular hospitalization, cardiovascular events, and sudden cardiac death in HD patients further corroborate a link between ALP and cardiovascular disease (6, (12) (13) (14) 25) . Other potential mechanisms by which elevation of ALP might be associated with cardiovascular morbidity and mortality include 25-hydroxyvitamin D deficiency and inflammation (38, 39) . To our knowledge, the present study is the first to show that ALP elevations are associated with increased mortality in PD patients. Many, but not all, studies (40, 41) show that increased ALP is associated with greater mortality across heterogeneous groups including HD patients, kidney transplant recipients, non-dialysisdependent CKD patients, and the general population (4) (5) (6) 8, 10, 11, 13, 32, (42) (43) (44) (45) . In contrast, Filipowicz et al. (40) and Yeoh and Sivaraman (41) recently demonstrated that skeletal ALP is not associated with increased serum C-reactive protein or death in CKD and non-CKD cohorts, suggesting that bone disease is unlikely to account for the observed associations of ALP with inflammation and mortality. However, the low representation of participants with advanced CKD in the aforementioned studies limits generalizability of the results to dialysis populations, and it is plausible that the associations between skeletal ALP and mortality may be different in PD patients than in individuals with lesser degrees of kidney dysfunction. In the only prior study to examine the ALPmortality association in PD patients, baseline ALP greater than 130 U/L was not associated with 6-month mortality by logistic regression (41); however, interpretation of those data is limited by small sample size, short-term follow-up and inattention to finer gradations of ALP, and Figure 4 -All-cause mortality hazard ratios, with 95% confidence intervals (CIs), for baseline alkaline phosphatase (AP) and parathyroid hormone (PTH) quintiles in 9244 peritoneal dialysis patients. The Cox regression models included the exposure of interest, entry calendar quarter, age, sex, race or ethnicity, diabetes, congestive heart failure, atherosclerotic heart disease, peripheral vascular disease, other cardiac disease, active tobacco use, dialysis vintage, primary insurance, marital status, body mass index, ferritin, serum albumin, total iron binding capacity, bicarbonate, creatinine, white blood cell count, lymphocyte percentage, normalized protein catabolic rate, calcium, phosphorus, hemoglobin, and weekly dose of erythropoiesis-stimulating agents.
NOVEMBER 2014 -VOL. 34, NO. 7 PDI censoring events. In contrast, our findings suggest that, when examined as a baseline measurement, elevated ALP is associated with increased mortality in PD patients, even within high-normal ranges. Given that several therapeutic interventions (activated vitamin D and calcimimetics, for example) have been shown to lower ALP concentrations, further study is needed to determine if a reduction in serum ALP leads to improved outcomes (46, 47) .
It is important to note that, in contrast with the analyses of baseline measurements, the analyses using First, time-averaged analyses may better capture the impact of long-term, cumulative ALP exposure. In contrast, baseline ALP might be subject to misclassification and subsequent bias because of single-point-in-time measurements. Thus, findings from the time-averaged analyses might represent the long-term effects of adynamic bone disease in which complications of fracture, hypercalcemia, and cardiovascular calcification may mitigate any survival benefit conferred by low ALP concentrations (48) (49) (50) . However, given the trend toward lower mortality risk in patients from the lowest timeaveraged ALP strata, it is also possible that the analyses were insufficiently powered because the prevalence of PD patients in this category was notably low. Additional studies are needed to clarify the prognostic implications of low ALP in PD patients.
In the present study, we also observed a U-shaped association between time-averaged PTH and mortality in PD patients. In studies of HD patients, high PTH has been associated with increased death risk, presumably because of effects on vascular calcification (2, 8, 51, 52) . Furthermore, studies using serial measurements have also suggested that low PTH is associated with increased mortality (8) . In addition to adynamic bone disease, risk factors for low PTH (advanced age, white race, high calcium load, protein-energy wasting) and their potential sequelae (withholding of activated vitamin D and calcimimetics) might serve as links between low PTH and mortality (20) . Few prior studies have examined mortality-predictability using PTH exclusively in PD patients, and the available results are mixed. In two small studies that used different PTH cut-offs, neither low nor high PTH was associated with mortality (53) . In contrast, low PTH concentrations (<65 pg/ mL and 65 -199 pg/mL) compared with concentrations greater than 200 pg/mL were associated with increased death risk in one study of PD patients (53, 54) . However, for PTH concentrations exceeding 200 pg/ mL, a distinction was not made between concentrations of 300 pg/mL or less and concentrations greater than 300 pg/mL, and serial measurements were not considered. To address that uncertainty, we examined baseline and time-averaged PTH with finer granularity. In baseline analyses, we did not observe a significant association with death risk, but in time-averaged analyses, a U-shaped association emerged.
Early studies suggested that, compared with their HD counterparts, PD patients have a disproportionately higher prevalence of low bone turnover, but those investigations were largely conducted before adoption of lower-calcium PD solutions (55) . For that reason, we compared the distribution of and mortality-predictability for bone turnover markers according to dialysis modality. More than 60% of PD and HD patients manifested ALP concentrations consistent with normal-to-low bone Unadjusted models included the exposure of interest and entry calendar quarter. Case-mix adjusted models included unadjusted model covariates, plus age, sex, race or ethnicity, diabetes, congestive heart failure, atherosclerotic heart disease, peripheral vascular disease, other cardiac disease, active tobacco use, dialysis vintage, primary insurance, marital status, body mass index, and ferritin. Fully-adjusted models included case-mix model covariates, plus serum albumin, total iron binding capacity, bicarbonate, creatinine, white blood cell count, lymphocyte percentage, normalized protein catabolic rate, calcium, phosphorus, hemoglobin, and weekly dose of erythropoiesis-stimulating agents.
NOVEMBER 2014 -VOL. 34, NO. 7 PDI turnover. However, in contrast with earlier data, PD patients had higher odds of having an increased PTH concentration, even after accounting for case-mix and laboratory differences. The disproportionate risk of high bone turnover disease in PD patients compared with HD patients might relate to losses of vitamin D in peritoneal effluent and poor adherence to oral vitamin D therapy, but further study is needed (29) .
When comparing the mortality-predictability for timeaveraged ALP in HD and PD patients (using PD patients with normal concentrations as the reference group), PD patients experienced increased mortality at higher ALP concentrations, but HD patients experienced increased mortality at all ALP concentrations, particularly in the lowest and highest strata. Similarly, when HD patients were compared with PD patients having normal PTH levels, a U-shaped association was observed between time-averaged PTH and mortality in PD patients, but HD patients experienced increased mortality at all PTH concentrations, especially the lowest and highest categories. Despite extensive adjustment for covariates, residual confounding on the basis of comorbidity status and therapeutic management of PD patients compared with HD patients might yet remain; nevertheless, the data suggest that ALP and PTH derangements have negative prognostic implications in PD and HD patients alike.
Our study has several strengths, including its contemporary timeframe, a large sample of PD and HD patients, uniform laboratory measurements conducted in a single facility, extended follow-up, and extensive measurement and adjustment for confounders. Yet several limitations bear mention. First, we are unable to confirm that elevated ALP measurements originate from a skeletal source or that CKD-MBD pathways underlie the ALP-mortality association. However, analyses adjusted for elevations in a liver enzyme as a possible confounder did not change for changes in dialysis modality over time (that is, transition from PD to HD), which might also have contributed to residual confounding. Fourth, excluded patients differed from those who were included, which may have biased the results. Lastly, as with all observational studies, our findings do not prove that the associations of ALP and PTH with mortality are causal.
CONCLUSIONS
Our findings suggest that elevated ALP and both high and low PTH are associated with increased mortality in PD patients. Given the biologic plausibility of an ALP-cardiovascular disease link, the consistency of epidemiologic data across heterogeneous populations, ease of availability, and ability to lower ALP with medications, ALP might be a promising tool for CKD-MBD management in PD patients. Further studies are now needed to confirm our findings, elucidate underlying mechanisms, and determine if correction of ALP and PTH to target ranges improves outcome in PD patients.
